Kindly refer to the outcome of the Board Meeting held on 01-09-2026

GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 REGD. OFFICE & FACTORY: 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA TEL: 0260-2430027 / 2400639, E-mail: hrm@gtbl.in.net 1 September 2026 Listing Department Department of Corporate Services National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block-G Phiroze Jeejeebhoy Towers, Dalal Street Bandra Kurla Complex Mumbai 400001 Bandra East, Mumbai 400051 Symbol: GUJTHEM Scrip Code: 506879 Sub.: Outcome of the Board meeting held on September 1, 2026. Dear Sir/Madam With reference to the captioned subject and as per the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (the SEBI Listing Regulations), this is to inform you that the Board of Directors of Gujarat Themis Biosyn Limited (the Company) at their meeting held today ie on September 1, 2026, has, inter-alia, approved the following. The issuance of up to 82,10,786 fully paid-up equity shares of the Company of face value of Rs. 1 each at an issue price of Rs. 408/- per equity share (including a securities premium of Rs. 407), aggregating up to Rs. 335,00,00,688/-, to the proposed allottees, as detailed in Annexure A, by way of a preferential issue on a private placement basis (the Preferential Issue), in accordance with the provisions of Section 42, 62 and applicable provisions of the Companies Act 2013, SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, SEBI Listing Regulations and applicable laws, and subject to necessary approvals including approval of the shareholders and Stock Exchanges. The disclosures as required under Regulation 30 of SEBI Listing Regulations are given in Annexures attached herewith. The meeting of the Board of Directors commenced at 2:30 p.m. and concluded at 3:35 p.m. This is for your information and records. Yours faithfully For Gujarat Themis Biosyn Limited Vineet Gawankar Company Secretary & Compliance Officer Encl.: As above GUJARAT THEMIS BIOSYN LIMITED Annexure A Sr. Particulars Details 1 Type of securities proposed to be Fully paid-up equity Shares of the Company having issued (viz. equity shares, face value of Rs. 1 each at an issue price of Rs. convertibles, etc. 408/- each. 2 Type of issuance (further public Preferential allotment offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.) 3 Total number of securities proposed The issue of up to 82,10,786 Equity Shares of the to be issued or the total amount for Company of face value of Rs. 1 each, as detailed in which the securities will be issued Annexure A (Investors) by way of a preferential (approximately) issue on a private placement basis at the issue price of Rs. 408/- per equity share including a Securities Premium of Rs. 407, aggregating Rs. 335,00,00,688/- in accordance with Chapter V of the SEBI ICDR Regulations, and subject to necessary approvals. 4 In case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s): a) Name of the investors The list of Proposed Allottees is given as Annexure b) Post allotment of securities - Not Applicable – To be done post allotment outcome of the subscription c) Issue price Equity Share of face value of Rs. 1 each at Issue Price of Rs. 408 per Equity Share. d) Number of investors Up to 5. e) In case of convertibles - intimation Not Applicable on conversion of securities or on lapse of the tenure of the instrument Annexure A (List of proposed allottees) No. Name of Investors / propose allottees No. of equity Amount to be paid, shares proposed in Rs. to be allotted 1 Pharmaceutical Business Group (India) Limited 61,27,453 250,00,00,824 (Promoter group) 2 Yusuf Khwaja Hamied 2,45,100 10,00,00,800 3 Special Situation India Fund 4,59,558 18,74,99,664 4 India Special Assets Fund III 6,83,823 27,89,99,784 5 ISAF III Onshore Fund 6,94,852 28,34,99,616 Investors mentioned at Sr. 2, 3, 4 and 5 are belong to non-promoter / non-promoter group.